---
title: "Diabetes testing, undiagnosed burden and care cascade in Kenya: Findings from the 2015 STEPwise su"
id: "medrxiv-7-diabetes-testing-care-cascade-and-the-burden-of-undiagnosed-diabetes-in-kenya"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-diabetes-testing-care-cascade-and-the-burden-of-undiagnosed-diabetes-in-kenya"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.29.26364371v1?rss=1"
published_at: "2026-10-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Diabetes testing, undiagnosed burden and care cascade in Kenya: Findings from the 2015 STEPwise su
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-diabetes-testing-care-cascade-and-the-burden-of-undiagnosed-diabetes-in-kenya
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.29.26364371v1?rss=1)
- **Published At:** 2026-10-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study used the nationally representative 2015 Kenya WHO STEPwise survey to assess **diabetes** testing coverage, prevalence, the proportion of **undiagnosed** cases, and progression through the **diabetes care cascade** among adults aged 18–69 years. - Analysis included 4,167 participants after excluding those with missing fasting plasma glucose (FPG) and those outside the 18–69 age range. - **Diabetes testing** was defined as self-reported prior blood glucose measurement by a health worker among those without known diabetes. - **Diabetes** was defined as FPG ≥7 mmol/L, a prior diagnosis, or current diabetes treatment. - Weighted prevalence of testing was 11.9% (95% CI: 9.7–14.5). The weighted prevalence of **diabetes** was 2.66% (95% CI: 2.06–3.42). - Among identified diabetes cases, 53.4% (95% CI: 39.0–67.4) were previously **undiagnosed**. - Care cascade losses: 46.9% of people with diabetes were aware of their diagnosis; 40.8% of those aware were on treatment; and 26.4% of those on treatment had achieved **glycaemic control**. - Higher testing prevalence was seen in older adults, those with tertiary education, obese participants, and people with hypertension; lower testing was observed among younger adults, those with no formal education, and residents of the North Eastern region. - Multivariable factors associated with higher odds of testing included older age (60–69 years: aOR 6.29), tertiary education (aOR 2.65), poorest wealth quintile (aOR 8.42), obesity (aOR 2.13), and hypertension (aOR 1.64); reported confidence intervals were included in the source. - The authors conclude that **diabetes testing coverage** in Kenya is low, a large share of cases are **undiagnosed**, and there are substantial losses across the **care cascade**, highlighting gaps in early diagnosis, linkage to care, treatment uptake, and control. - The study recommends strengthening integrated screening and care services, focusing on underserved and high-risk groups. Ethical approvals and data availability are reported in the source.
## Clinical Analysis & Structured Key Points
Diabetes testing, care cascade and the burden of undiagnosed diabetes in Kenya. Evidence from the 2015 Kenya STEPwise survey. | medRxiv Skip to main content Diabetes testing, care cascade and the burden of undiagnosed diabetes in Kenya. Evidence from the 2015 Kenya STEPwise survey. Catherine Akoth , Chloe V Thomas , James Odhiambo Oguta , Elvis Omondi Achach Wambiya , View ORCID Profile Peter J Dodd doi: https://doi.org/10.64898/2026.09.29.26364371 Catherine Akoth 1 The University of Sheffield; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: caodhiambo1{at}sheffield.ac.uk Chloe V Thomas 1 The University of Sheffield; Find this author on Google Scholar Find this author on PubMed Search for this author on this site James Odhiambo Oguta 1 The University of Sheffield; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elvis Omondi Achach Wambiya 2 African Population and Health Research Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site Peter J Dodd 1 The University of Sheffield; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Peter J Dodd Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Diabetes is a growing public health challenge globally, with a disproportionate burden occurring in low- and middle-income countries (LMICs). In Kenya, limited evidence exists on type 2 diabetes mellitus (T2DM) screening coverage, undiagnosed diabetes, and progression through the diabetes care cascade. This study assessed the prevalence and determinants of T2DM testing, quantified undiagnosed T2DM, and examined the T2DM care cascade in Kenya. Methods: We analysed data from the 2015 Kenya WHO STEPwise survey, a nationally representative cross-sectional survey of adults aged 18–69 years. The analysis included 4,167 participants after excluding individuals with missing fasting plasma glucose (FPG) measurements and those below the age of 18 and above 69 years. Diabetes testing was defined as self-reported prior blood glucose measurement by a health worker among individuals without known diabetes. Diabetes was defined as FPG ≥7 mmol/L, previous diagnosis, or current diabetes treatment. Weighted prevalence estimates with 95% confidence intervals (CI) were calculated. Univariable and multivariable logistic regression analyses were conducted to identify factors associated with diabetes screening while accounting for the complex survey design. Results: Overall, 11.9% (95% CI: 9.7–14.5) of participants reported ever being tested for diabetes. The weighted prevalence of diabetes was 2.66% (95% CI: 2.06–3.42), while 53.4% (95% CI: 39.0–67.4) of diabetes cases were previously undiagnosed. Testing prevalence was highest among older adults, individuals with tertiary education, obese participants, and those with hypertension, but lowest among younger adults, individuals with no formal education, and residents of the North Eastern region. Among individuals with diabetes, 46.9% were aware of their diagnosis, 40.8% of those aware were on treatment, and only 26.4% of those on treatment had achieved glycaemic control. In multivariable analysis, older age (60–69 years: aOR=6.29, 95% CI: 3.66–10.79), tertiary education (aOR=2.65, 95% CI: 1.33–5.27), poorest wealth quintile (aOR=8.42, 95% CI: 4.11–17.24), obesity (aOR=2.13, 95% CI: 1.41–3.21), and hypertension (aOR=1.64, 95% CI: 1.21–2.23) were significantly associated with increased odds of diabetes testing. Conclusion: Diabetes testing coverage in Kenya remains low, with more than half of diabetes cases remaining undiagnosed and substantial losses occurring across the diabetes care cascade. These findings highlight critical gaps in early diagnosis, linkage to care, treatment uptake, and glycaemic control. Strengthening integrated diabetes screening and care services, particularly for underserved and high-risk populations, is essential to improve early detection and continuity of care in Kenya. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The 2015 Kenya WHO STEPwise Survey of Non-Communicable Disease Risk Factors was conducted following ethical approval from the Kenya Medical Research Institute (KEMRI) Ethics Review Committee and obtaining informed consent of all survey participants. The analysis was conducted using de-identified survey data, with no access to identifiable participant information. Therefore, additional ethical approval was not sought for the present secondary analysis. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data used for this study are available to download from the Kenya Nationional Data Archive (https://statistics.knbs.or.ke/nada/index.php/catalog/24) upon request from Kenya National Bureau of Statistics. https://statistics.knbs.or.ke/nada/index.php/catalog/24 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted October 02, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Diabetes testing, care cascade and the burden of undiagnosed diabetes in Kenya. Evidence from the 2015 Kenya STEPwise survey. Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Diabetes testing, care cascade and the burden of undiagnosed diabetes in Kenya. Evidence from the 2015 Kenya STEPwise survey. Catherine Akoth , Chloe V Thomas , James Odhiambo Oguta , Elvis Omondi Achach Wambiya , Peter J Dodd medRxiv 2026.09.29.26364371; doi: https://doi.org/10.64898/2026.09.29.26364371 Share This Article: Copy Citation Tools Diabetes testing, care cascade and the burden of undiagnosed diabetes in Kenya. Evidence from the 2015 Kenya STEPwise survey. Catherine Akoth , Chloe V Thomas , James Odhiambo Oguta , Elvis Omondi Achach Wambiya , Peter J Dodd medRxiv 2026.09.29.26364371; doi: https://doi.org/10.64898/2026.09.29.26364371 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (624) Allergy and Immunology (911) Anesthesia (339) Cardiovascular Medicine (4877) Dentistry and Oral Medicine (483) Dermatology (421) Emergency Medicine (658) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1640) Epidemiology (16053) Forensic Medicine (34) Gastroenterology (1217) Genetic and Genomic Medicine (7119) Geriatric Medicine (736) Health Economics (1072) Health Informatics (5113) Health Policy (1447) Health Systems and Quality Improvement (1790) Hematology (589) HIV/AIDS (1353) Infectious Diseases (except HIV/AIDS) (16351) Intensive Care and Critical Care Medicine (1183) Medical Education (677) Medical Ethics (156) Nephrology (729) Neurology (7374) Nursing (370) Nutrition (1100) Obstetrics and Gynecology (1259) Occupational and Environmental Health (1010) Oncology (3650) Ophthalmology (1066) Orthopedics (399) Otolaryngology (459) Pain Medicine (482) Palliative Medicine (142) Pathology (711) Pediatrics (1821) Pharmacology and Therapeutics (741) Primary Care Research (775) Psychiatry and Clinical Psychology (5974) Public and Global Health (9823) Radiology and Imaging (2458) Rehabilitation Medicine and Physical Therapy (1476) Respiratory Medicine (1255) Rheumatology (648) Sexual and Reproductive Health (783) Sports Medicine (588) Surgery (786) Toxicology (107) Transplantation (310) Urology (297)
## Related Clinical Research

- [Self-Management Program Lowers HbA1c, eGFR, SBP, LDL-C in High-Risk DKD Patients with Type 2 Diabe](https://medichelpline.com/clinical-feed/plos-one-11-effectiveness-of-a-self-management-intervention-on-clinical-outcomes-among.md)
- [Machine learning classification of pre-metabolic syndrome vs metabolic syndrome in Thai adults](https://medichelpline.com/clinical-feed/plos-one-17-classification-of-pre-metabolic-syndrome-and-metabolic-syndrome-using-machine.md)
- [Left ventricular hypertrophy and brain atrophy in type 2 diabetes: findings from the D2 cohort](https://medichelpline.com/clinical-feed/medrxiv-0-left-ventricular-hypertrophy-brain-atrophy-and-cognitive-decline-in-type-2.md)
- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- [Testosterone Therapy in Men Often Prescribed Inconsistently with Guidelines, ENDO 2026 Study Shows](https://medichelpline.com/clinical-feed/endocrine-news-0-video-testosterone-therapy-in-men-may-be-overprescribed-inconsistent-with.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.